Clinical Trials - Physician

Clinical Trials - Physician

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
Randomized Trial of Avelumab Plus Cetuximab vs Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (A091802) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer (S1806) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Erlotinib vs Placebo in Patients with Completely Resected EGFR Mutant NonSmall Cell Lung Cancer (A081105) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (S1706) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (A021502) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients who Smoke Cigarettes (A221401)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Registry for Lung Screening Excellence
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study Comparing Tislelizumab + Platinum And Fluoropyrimidine Versus Placebo Plus Platinum And Fluoropyrimidine As First-Line Treatment In Patients With Locally Advanced Unresectable Or Metastatic Gastric or GEJ Adenocarcinoma (BGBA317- 305) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress1) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer; (AFT-19) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of FOLFIRINOX plus Ramucirumab versus FOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients (GI14-198) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study Of High Dose Interleukin 2 Vs High Dose Interleukin 2 Plus Entinostat In Untreated Advanced Renal Cell Carcinoma (HCRN GU17-289) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors (PCYC-1128-CA) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (MEL 16-252 SALVO) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of mFolfox6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatci Colorectal Cancer (GI004) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer (EA2165) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of Pevonedistat Plus Azacitidine versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low Blast Acute Myelogenous Leukemia(Pevonedistat-3001) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study Testing the Addition of Nivolumab Pre and Post Nephrectomy in Patients with Renal Cell Carcinoma (EA8143) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (CONNECT) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents (SUMMIT)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Treatment Resistance Following AntiCancer Therapies (18150)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Treatment with Ipilimumab and Nivolumab for Rare Cancers (DART: Dual Anti-CRLA-4 and Anti-PD-1 Blockade in Rare Tumors) (S1609)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Trial Comparing Paclitaxel, Ifosfamide, and Cisplatin with High-Dose Chemo Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors (A031102) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Trial of Neoadjuvant AMG-232 Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (DT001) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (GU006) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members